Stockscreener 앱 받기
0.60%
전일 마감가:
$127.81
열려 있는:
$129.01
하루 거래량:
316.27K
Relative Volume:
0.38
시가총액:
$9.71B
수익:
$12.82B
순이익/손실:
$936.34M
주가수익비율:
11.98
EPS:
10.74
순현금흐름:
$1.47B
1주 성능:
-8.40%
1개월 성능:
-9.97%
6개월 성능:
-25.93%
1년 성능:
-4.03%
1일 변동 폭
$126.50
$129.64
1주일 범위
$126.07
$141.97
52주 변동 폭
$126.07
$179.60
다비타 Stock (DVA) Company Profile
명칭
Davita Inc
전화
310-536-2668
주소
2000 16TH STREET, DENVER, CO
DVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
128.66 | 10.62B | 12.82B | 936.34M | 1.47B | 10.74 |
|
HCA
Hca Healthcare Inc
|
371.12 | 85.13B | 72.70B | 5.97B | 7.29B | 23.79 |
|
THC
Tenet Healthcare Corp
|
162.15 | 14.16B | 20.52B | 1.46B | 1.41B | 15.12 |
|
FMS
Fresenius Medical Care Ag Adr
|
23.77 | 14.33B | 20.92B | 666.06M | 1.85B | 1.1422 |
|
EHC
Encompass Health Corp
|
116.07 | 11.48B | 5.51B | 494.70M | 386.40M | 4.84 |
다비타 Stock (DVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-06 | 개시 | Barclays | Equal Weight |
| 2023-08-07 | 업그레이드 | UBS | Neutral → Buy |
| 2022-11-01 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-10-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-08-19 | 재개 | UBS | Buy |
| 2022-06-21 | 재확인 | BofA Securities | Underperform |
| 2021-09-10 | 개시 | Cowen | Market Perform |
| 2021-08-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-03-26 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-03 | 개시 | Deutsche Bank | Buy |
| 2018-12-14 | 개시 | Barclays | Overweight |
| 2018-11-28 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | 개시 | UBS | Sell |
| 2018-11-08 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-01-04 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2017-12-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-12-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
다비타 주식(DVA)의 최신 뉴스
DaVita Inc. (NYSE:DVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Barclays Updates DaVita (DVA) with Lower Price Target to $160 | - GuruFocus
DaVita 2025 Q2 Earnings Net Income Falls 8.2% Despite Revenue Growth - AInvest
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands - The Globe and Mail
DaVita Inc. Stock Dives 8.5% on Declining Treatment Volumes and Forecast CutNews and Statistics - IndexBox
Why DaVita (DVA) Stock Is Nosediving - Yahoo Finance
Huge healthcare breach sees nearly a million patients hit following DaVita ransomware attackmake sure you're safe - TechRadar
DaVita stock hits 52-week low at $131.09 amid market fluctuations - Investing.com Nigeria
Over 900K hit by DaVita ransomware hack - SC Media
DaVita 2025 Q2 Earnings Mixed Performance as Net Income Falls 8.2% - AInvest
DaVita Inc. Exceeds Expectations with Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
DaVita reiterates $2.01B–$2.16B adjusted operating income guidance for 2025 as cost controls offset volume headwinds - MSN
DaVita HealthCare: Q2 Earnings Snapshot - Greenwich Time
DaVita Inc (DVA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Resilience and ... - uk.finance.yahoo.com
DaVita Inc (DVA) Q2 2025 Earnings Call Highlights: Navigating Ch - GuruFocus
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
DaVita Inc. (DVA): Mastering Capital Allocation in a High-Margin Dialysis Industry - AInvest
Strategic Cost Management as the Cornerstone of DaVita's Resilient Operational Performance in 2025 - AInvest
Can DaVita's Pattern of Revenue Outperformance Shape Its Broader Growth Narrative? (DVA) - simplywall.st
DaVita Outpaces Expectations Despite Cyberattack And Hurricane Setbacks - Finimize
Earnings call transcript: DaVita Q2 2025 beats estimates, stock dips - Investing.com
DaVita Inc reports results for the quarter ended June 30Earnings Summary - TradingView
DaVita’s (NYSE:DVA) Q2 Sales Beat Estimates - TradingView
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
DAVITA INC. SEC 10-Q Report - TradingView
DaVita beats quarterly profit on steady demand for dialysis services - TradingView
DaVita HealthCare Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
DaVita Inc. Q2 Sales Increase - Nasdaq
DaVita Inc Q2 2025 Earnings: Revenue Surpasses Estimates at $3.3 - GuruFocus
DaVita earnings beat by $0.17, revenue topped estimates By Investing.com - Investing.com South Africa
DaVita earnings beat by $0.17, revenue topped estimates - Investing.com Australia
DaVita Inc Q2 2025 Earnings: Revenue Surpasses Estimates at $3.38 Billion, Adjusted EPS Beats at $2.95 - GuruFocus
DaVita Inc. 2nd Quarter 2025 Results - PR Newswire
Berkshire Hathaway buys $106.5M in Sirius XM, cuts $230M in DaVita - MSN
Dialysis company DaVita says more than 900,000 people affected by April ransomware attack - The Record from Recorded Future News
Investors Aren't Entirely Convinced By DaVita Inc.'s (NYSE:DVA) Earnings - simplywall.st
Berkshire Hathaway Boosts Sirius XM Stake to 37%, Sells DaVita Shares - WebProNews
Warren Buffett's Berkshire Hathaway Offloads $230 Million In DaVita Stock Ahead Of Q2 Earnings - inkl
Berkshire Hathaway Buys More Sirius XM Stock, Sells DaVita Shares in Recent Days - Barron's
Berkshire Hathaway buys $106.5M in Sirius XM, cuts $230M in DaVita (SIRI:NASDAQ) - Seeking Alpha
Insider Transactions Reported | DaVita(DVA)saw insider trading activity on 8/4/2025 - AInvest
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization - Stock Titan
DaVita (DVA) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Is DaVita Inc. stock overvalued or undervaluedMaximize returns with strategic trading plans - Jammu Links News
Is DaVita Inc. a good long term investmentBreakout portfolio performance - Jammu Links News
Is it the right time to buy DaVita Inc. stockInvest smarter with advanced market data - Jammu Links News
What drives DaVita Inc. stock priceAchieve consistent returns with proven methods - Jammu Links News
What is DaVita Inc. company’s growth strategyExplosive trading growth - Jammu Links News
How strong is DaVita Inc. company’s balance sheetSuperior portfolio returns - Jammu Links News
DaVita Inc. Stock Analysis and ForecastUnlock powerful trading techniques - Jammu Links News
다비타 (DVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
0.23%
자본화:
|
볼륨(24시간):